CJS Securities analyst Jonathan Tanwanteng upgrades Vicor (NASDAQ:VICR) from Market Perform to Market Outperform.
Argenx Announces U.S. FDA Acceptance Of Biologics License Application For Subcutaneous Efgartigimod In Generalized Myasthenia Gravis With Priority Review; PDUFA Date Is March 20, 2023
- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023
- Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at day
